JP2010536896A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536896A5
JP2010536896A5 JP2010522210A JP2010522210A JP2010536896A5 JP 2010536896 A5 JP2010536896 A5 JP 2010536896A5 JP 2010522210 A JP2010522210 A JP 2010522210A JP 2010522210 A JP2010522210 A JP 2010522210A JP 2010536896 A5 JP2010536896 A5 JP 2010536896A5
Authority
JP
Japan
Prior art keywords
leukemia
acute
chronic
lymphocytic leukemia
myeloid leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010522210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536896A (ja
JP5524840B2 (ja
Filing date
Publication date
Priority claimed from DE102007041115A external-priority patent/DE102007041115A1/de
Application filed filed Critical
Publication of JP2010536896A publication Critical patent/JP2010536896A/ja
Publication of JP2010536896A5 publication Critical patent/JP2010536896A5/ja
Application granted granted Critical
Publication of JP5524840B2 publication Critical patent/JP5524840B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010522210A 2007-08-30 2008-08-06 チアジアジノン誘導体 Expired - Fee Related JP5524840B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007041115.6 2007-08-30
DE102007041115A DE102007041115A1 (de) 2007-08-30 2007-08-30 Thiadiazinonderivate
PCT/EP2008/006466 WO2009030333A1 (de) 2007-08-30 2008-08-06 Thiadiazinonderivate

Publications (3)

Publication Number Publication Date
JP2010536896A JP2010536896A (ja) 2010-12-02
JP2010536896A5 true JP2010536896A5 (enExample) 2014-04-03
JP5524840B2 JP5524840B2 (ja) 2014-06-18

Family

ID=39952448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522210A Expired - Fee Related JP5524840B2 (ja) 2007-08-30 2008-08-06 チアジアジノン誘導体

Country Status (16)

Country Link
US (1) US8211886B2 (enExample)
EP (1) EP2181111B1 (enExample)
JP (1) JP5524840B2 (enExample)
KR (1) KR20100065171A (enExample)
CN (1) CN101784544B (enExample)
AR (1) AR068130A1 (enExample)
AU (1) AU2008295193B2 (enExample)
BR (1) BRPI0816058A2 (enExample)
CA (1) CA2698062C (enExample)
DE (1) DE102007041115A1 (enExample)
EA (1) EA017393B1 (enExample)
ES (1) ES2426356T3 (enExample)
IL (1) IL204127A (enExample)
MX (1) MX2010002096A (enExample)
WO (1) WO2009030333A1 (enExample)
ZA (1) ZA201002218B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795964A (en) 1980-12-04 1982-06-15 Morishita Seiyaku Kk Preparation of 2-substituted-3(2h)-pyridazinone derivative
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
DE4310699A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Thiadiazinone
AU691673B2 (en) 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
BR9813998A (pt) 1997-11-19 2000-09-26 Kowa Co Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
MXPA04003668A (es) 2001-10-31 2004-07-22 Merck Patent Gmbh Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
DE102005055354A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102006037478A1 (de) * 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate

Similar Documents

Publication Publication Date Title
JP2012513418A5 (enExample)
CN110545800A (zh) 用于靶向活化cd44分子的纳米钙载体递送系统、其制备方法和用途
JP2010532774A5 (enExample)
JP2012501986A5 (enExample)
JP2010538767A5 (enExample)
WO2009108856A3 (en) Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2009105513A8 (en) Novel compounds and methods for therapy
MY160445A (en) Dual Variable Domain Immunoglobulins And Uses Thereof
CA2726087A1 (en) Dual variable domain immunoglobulins and uses thereof
JP2009537552A5 (enExample)
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
JP2013074936A5 (enExample)
WO2009074328A8 (en) Methods and nucleic acids for analyses of lung carcinoma
EP3702782A3 (en) Methods and compositions for amplified electrochemiluminescence detection
EP4279925A3 (en) Dulaglutide for the treatment of chronic kidney disease
WO2009127414A3 (en) Inhibition of angiogenesis and tumor metastasis
JP2011520996A5 (enExample)
JP2009519974A5 (enExample)
JP2008542528A5 (enExample)
JP2009532412A5 (enExample)
WO2011051271A3 (en) Prostate tumor markers and methods of use thereof
MX2009011388A (es) Inhibidores de polimerasa y su uso para el tratamiento de tumores.
BRPI0822415A2 (pt) Conjugado de hidróxipolímero modificado, uso de conjugado de hidroxipolímero modificado, composição para matar tumor, e, métodos para produzir o conjugado de hidroxipolímero modificado e para tratar câncer.
CL2014001823A1 (es) Procedimiento de preparacion estereoselectiva de un compuesto derivado de 9-hidroxi-5-oxo-1,4-diaza-espiro [5.5] undecano; compuestos intermediarios; uso en el tratamiento de enfermedades tumorales, enfermedades del pulmon y de las vias respiratorias.